The Trump administration has taken a significant step in federal drug policy. Officials announced the reclassification of medical marijuana to a less restrictive category. The change marks a shift after decades of strict federal control.
Acting Attorney General Todd Blanche signed the order this week. It moves state-licensed medical marijuana from Schedule I to Schedule III. Schedule I drugs are considered highly dangerous with no accepted medical use.
The new classification recognizes marijuana’s medical value and lower abuse potential. Schedule III drugs include substances like ketamine and anabolic steroids.
The decision follows a December 2025 executive order from President Donald Trump. That directive pushed federal agencies to accelerate marijuana research and policy reform.
“This is the most significant federal advancement in cannabis policy in over 50 years,” one report noted.
Policy Shift and Medical Implications
The reclassification is expected to ease restrictions on medical research. Scientists can now study cannabis without the same legal barriers.
It also allows state-licensed cannabis businesses to claim federal tax deductions. Previously, those deductions were prohibited under federal law.
Supporters say the move aligns federal policy with widespread state practices. Nearly all states allow some form of medical marijuana use.
Advocates argue the change will improve patient access to treatment. It may also encourage more doctors to consider cannabis-based therapies.
However, the policy stops short of full legalization. Recreational marijuana remains illegal under federal law.
Criticism and Limits of Reform
Despite praise, critics say the move does not go far enough. The reclassification does not erase past marijuana convictions.
Advocacy groups have called for broader criminal justice reforms. They argue that thousands remain affected by earlier drug laws.
“This change benefits industry, but not those still paying the price,” critics have said.
Some lawmakers also raised concerns about health risks and drug potency. Others argue the shift sends mixed signals about marijuana safety.
The administration has signaled further action may follow. A Drug Enforcement Administration hearing is scheduled for June. Officials will consider broader marijuana rescheduling.